{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T04:37:23Z","timestamp":1775018243942,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,7,4]],"date-time":"2008-07-04T00:00:00Z","timestamp":1215129600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1007\/s00213-008-1207-7","type":"journal-article","created":{"date-parts":[[2008,7,2]],"date-time":"2008-07-02T23:44:12Z","timestamp":1215042252000},"page":"317-331","source":"Crossref","is-referenced-by-count":53,"title":["Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study"],"prefix":"10.1007","volume":"200","author":[{"given":"Daniel E.","family":"Casey","sequence":"first","affiliation":[]},{"given":"Earl E.","family":"Sands","sequence":"additional","affiliation":[]},{"given":"Jens","family":"Heisterberg","sequence":"additional","affiliation":[]},{"given":"Hwa-Ming","family":"Yang","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2008,7,4]]},"reference":[{"issue":"suppl 7","key":"1207_CR1","first-page":"22","volume":"62","author":"DB Allison","year":"2001","unstructured":"Allison DB, Casey DE (2001) Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 62(suppl 7):22\u201331","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"1207_CR2","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","volume":"27","author":"American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity","year":"2004","unstructured":"American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27(2):596\u2013601","journal-title":"Diabetes Care"},{"key":"1207_CR3","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890423349","volume-title":"Diagnostic and statistical manual of mental disorders, 4th edition, text revision (DSM-IV-TR)","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edition, text revision (DSM-IV-TR). American Psychiatric, Washington, DC"},{"key":"1207_CR4","first-page":"3","volume":"48","author":"A Avogaro","year":"2006","unstructured":"Avogaro A (2006) Insulin resistance: trigger or concomitant factor in the metabolic syndrome. Panminerva Med 48:3\u201312","journal-title":"Panminerva Med"},{"issue":"suppl 2, pt 1","key":"1207_CR5","first-page":"E425","volume":"273","author":"MA Banerji","year":"1997","unstructured":"Banerji MA, Lebowitz J, Chaiken RL, Gordon D, Kral JG, Lebovitz HE (1997) Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects. Am J Physiol 273(suppl 2, pt 1):E425\u2013E432","journal-title":"Am J Physiol"},{"issue":"suppl 2","key":"1207_CR6","first-page":"15S","volume":"118","author":"DE Casey","year":"2005","unstructured":"Casey DE (2005) Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med 118(suppl 2):15S\u201322S","journal-title":"Am J Med"},{"issue":"suppl 3","key":"1207_CR7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0924-977X(00)80412-5","volume":"10","author":"DE Casey","year":"2000","unstructured":"Casey DE, Van Vliet BJ, Feenstra R, Kruse CG, Long SK (2000) DU 127090: a highly potent, atypical dopamine receptor ligand\u2014behavioral effects of DU 127090 in Cebus non-human primates. Eur Neuropsychopharmacol 10(suppl 3):333","journal-title":"Eur Neuropsychopharmacol"},{"key":"1207_CR8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejphar.2006.01.051","volume":"535","author":"C Cosi","year":"2006","unstructured":"Cosi C, Carilla-Durand E, Assi\u00e9 MB, Ormi\u00e8re AM, Maraval M, Leduc N, Newman-Tancredi A (2006) Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Eur J Pharmacol 535:135\u2013144","journal-title":"Eur J Pharmacol"},{"key":"1207_CR9","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","volume":"60","author":"JM Davis","year":"2003","unstructured":"Davis JM, Chen N, Glick ID (2003) A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:553\u2013564","journal-title":"Arch Gen Psychiatry"},{"issue":"1 suppl 1","key":"1207_CR10","doi-asserted-by":"crossref","first-page":"S239","DOI":"10.1016\/S0920-9964(03)81240-9","volume":"60","author":"MH Vries De","year":"2003","unstructured":"De Vries MH, Udo de Haes J, Grahn\u00e9n A, Nyman L, Bergstr\u00f6m M, Wall A, Langstr\u00f6m B (2003) DU 127090: a novel partial dopamine agonist with antipsychotic activity: pilot study of dopamine D2 receptor occupancy after multiple oral administration of DU 127090 to healthy male volunteers, using 11C-raclopride by means of positron emission tomography. Schizophrenia Res 60(1 suppl 1):S239\u2013S240","journal-title":"Schizophrenia Res"},{"issue":"7","key":"1207_CR11","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1176\/appi.ps.53.7.882","volume":"53","author":"FB Dickerson","year":"2002","unstructured":"Dickerson FB, Pater A, Origoni AE (2002) Health behaviors and health status of older women with schizophrenia. Psychiatr Serv 53(7):882\u2013884","journal-title":"Psychiatr Serv"},{"issue":"4","key":"1207_CR12","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/schbul\/21.4.567","volume":"21","author":"LB Dixon","year":"1995","unstructured":"Dixon LB, Lehman AF, Levine J (1995) Conventional antipsychotic medications for schizophrenia. Schizophr Bull 21(4):567\u2013577","journal-title":"Schizophr Bull"},{"issue":"3","key":"1207_CR13","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/jama.287.3.356","volume":"287","author":"ES Ford","year":"2002","unstructured":"Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287(3):356\u2013359","journal-title":"JAMA"},{"issue":"1","key":"1207_CR14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3109\/10401230209147398","volume":"14","author":"J Gerlach","year":"2002","unstructured":"Gerlach J (2002) Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Ann Clin Psychiatry 14(1):47\u201357","journal-title":"Ann Clin Psychiatry"},{"key":"1207_CR15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.schres.2005.08.010","volume":"80","author":"DC Goff","year":"2005","unstructured":"Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, Lamberti S, D\u2019Agostino RB, Stroup TS, Davis S, Lieberman JA (2005) A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 80:45\u201353","journal-title":"Schizophr Res"},{"key":"1207_CR16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1176\/appi.ajp.162.1.118","volume":"162","author":"KA Graham","year":"2005","unstructured":"Graham KA, Perkins DO, Edwards LJ, Barrier RC Jr, Lieberman JA, Harp JB (2005) Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry 162:118\u2013123","journal-title":"Am J Psychiatry"},{"issue":"20","key":"1207_CR17","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","volume":"64","author":"PM Haddad","year":"2004","unstructured":"Haddad PM, Wieck A (2004) Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64(20):2291\u20132314","journal-title":"Drugs"},{"issue":"5","key":"1207_CR18","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/00131746-200309000-00003","volume":"9","author":"U Halbreich","year":"2003","unstructured":"Halbreich U, Kahn LS (2003) Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. J Psychiatr Pract 9(5):344\u2013353","journal-title":"J Psychiatr Pract"},{"key":"1207_CR19","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4088\/JCP.v64n0513","volume":"64","author":"T Heiskanen","year":"2003","unstructured":"Heiskanen T, Niskanen L, Lyytik\u00e4inen R, Saarinen PI, Hintikka J (2003) Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 64:575\u2013579","journal-title":"J Clin Psychiatry"},{"key":"1207_CR20","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ahj.2005.02.007","volume":"150","author":"CH Hennekens","year":"2005","unstructured":"Hennekens CH, Hennekens AR, Hollar D, Casey DE (2005) Schizophrenia and increased risks of cardiovascular disease. Am Heart J 150:1115\u20131121","journal-title":"Am Heart J"},{"key":"1207_CR21","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/S0920-9964(03)80847-2","volume":"60","author":"MB Hesselink","year":"2003","unstructured":"Hesselink MB, Van Vliet BJ, Ronken E, Tulp M, Long SK, Feenstra RW, Kruse CG (2003) DU 127090: a novel partial dopamine agonist with antipsychotic activity. High potency but low efficacy at dopamine D2 receptors in vitro. Schizophrenia Res 60:S108","journal-title":"Schizophrenia Res"},{"issue":"3","key":"1207_CR22","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/026988110401800308","volume":"18","author":"T Hirose","year":"2004","unstructured":"Hirose T, Uwahodo Y, Yamada S, Miwa T, Kikuchi T, Kitagawa H, Burris KD, Altar CA, Nabeshima T (2004) Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharm 18(3):375\u2013383","journal-title":"J Psychopharm"},{"key":"1207_CR23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/08039480600636296","volume":"60","author":"MP H\u00f8iberg","year":"2006","unstructured":"H\u00f8iberg MP, Nielsen B (2006) Antipsychotic treatment and extrapyramidal symptoms amongst schizophrenic inpatients. Nord J Psychiatry 60:207\u2013212","journal-title":"Nord J Psychiatry"},{"issue":"2","key":"1207_CR24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261\u2013276","journal-title":"Schizophr Bull"},{"key":"1207_CR25","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1073\/pnas.0611417104","volume":"104","author":"SF Kim","year":"2007","unstructured":"Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH (2007) Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. PNAS 104:3456\u20133459","journal-title":"PNAS"},{"key":"1207_CR26","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","volume":"28","author":"WK Kroeze","year":"2003","unstructured":"Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519\u2013526","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"1207_CR27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(98)00105-4","volume":"35","author":"S Leucht","year":"1999","unstructured":"Leucht S, Pitschel-Walz G, Abraham D, Kissling W (1999) Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 35(1):51\u201368","journal-title":"Schizophr Res"},{"issue":"4","key":"1207_CR28","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00023210-200418040-00005","volume":"18","author":"JA Lieberman","year":"2004","unstructured":"Lieberman JA (2004) Dopamine partial agonists. CNS Drugs 18(4):251\u2013267","journal-title":"CNS Drugs"},{"issue":"12","key":"1207_CR29","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353(12):1209\u20131223","journal-title":"N Engl J Med"},{"issue":"suppl 3","key":"1207_CR30","doi-asserted-by":"crossref","first-page":"S295","DOI":"10.1016\/S0924-977X(00)80321-1","volume":"10","author":"SK Long","year":"2000","unstructured":"Long SK, Feenstra R, Kruse CG, Van Vliet BJ (2000) DU 12790: a highly potent, atypical dopamine receptor ligand: partial agonist character in neurochemistry assays in vivo. Eur Neuropsychopharmacol 10(suppl 3):S295","journal-title":"Eur Neuropsychopharmacol"},{"key":"1207_CR31","first-page":"305","volume":"31","author":"KL Marquis","year":"2005","unstructured":"Marquis KL, Hertel P, Reinders JH, van der Neut M, Ronken E, Hesselink MB (2005) Bifeprunox: a novel atypical antipsychotic sharing dopamine D2 receptor partial agonism and serotonin 5-HT1A receptor agonism. Schizophr Bull 31:305","journal-title":"Schizophr Bull"},{"key":"1207_CR32","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2133\/dmpk.20.368","volume":"20","author":"A Matsui-Sakata","year":"2005","unstructured":"Matsui-Sakata A, Ohtani H, Sawada Y (2005) Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 20:368\u2013378","journal-title":"Drug Metab Pharmacokinet"},{"key":"1207_CR33","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1192\/bjp.183.6.534","volume":"183","author":"RG McCreadie","year":"2003","unstructured":"McCreadie RG, Scottish Schizophrenia Lifestyle Group (2003) Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 183:534\u2013539","journal-title":"Br J Psychiatry"},{"key":"1207_CR34","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","volume":"80","author":"JP McEvoy","year":"2005","unstructured":"McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Stroup TS, Lieberman JA (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trials and comparison with national estimates from NHANES III. Schiz Research 80:19\u201332","journal-title":"Schiz Research"},{"issue":"6","key":"1207_CR35","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4088\/JCP.v66n0614","volume":"66","author":"K Melkersson","year":"2005","unstructured":"Melkersson K (2005) Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry 66(6):761\u2013767","journal-title":"J Clin Psychiatry"},{"key":"1207_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2004.01.014","volume":"70","author":"JM Meyer","year":"2004","unstructured":"Meyer JM, Koro CE (2004) The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 70:1\u201317","journal-title":"Schizophr Res"},{"issue":"2","key":"1207_CR37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4088\/JCP.v59n0205","volume":"59","author":"CH Miller","year":"1998","unstructured":"Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA (1998) The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 59(2):69\u201375","journal-title":"J Clin Psychiatry"},{"issue":"suppl 1","key":"1207_CR38","first-page":"1","volume":"19","author":"JW Newcomer","year":"2005","unstructured":"Newcomer JW (2005) Second generation (atypical) antipsychotics and metabolic effects. A comprehensive literature review. CNS Drugs 19(suppl 1):1\u201393","journal-title":"CNS Drugs"},{"issue":"suppl 9","key":"1207_CR39","first-page":"25","volume":"67","author":"JW Newcomer","year":"2006","unstructured":"Newcomer JW (2006) Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiatry 67(suppl 9):25\u201330","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"1207_CR40","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archpsyc.59.4.337","volume":"59","author":"JW Newcomer","year":"2002","unstructured":"Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G (2002) Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59(4):337\u2013345","journal-title":"Arch Gen Psychiatry"},{"key":"1207_CR41","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1017\/S1461145704005000","volume":"8","author":"A Newman-Tancredi","year":"2005","unstructured":"Newman-Tancredi A, Assi\u00e9 MB, Leduc N, Ormi\u00e8re AM, Danty N, Cosi C (2005) Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol 8:341\u2013356","journal-title":"Int J Neuropsychopharmacol"},{"issue":"13","key":"1207_CR42","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.295.13.1549","volume":"295","author":"CL Ogden","year":"2006","unstructured":"Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM (2006) Prevalence of overweight and obesity in the United States, 1999\u20132004. JAMA 295(13):1549\u20131555","journal-title":"JAMA"},{"issue":"1","key":"1207_CR43","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.jcp.0000150223.31007.e0","volume":"25","author":"V O\u2019Keane","year":"2005","unstructured":"O\u2019Keane V, Meaney AM (2005) Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol 25(1):26\u201331","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"1207_CR44","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00002018-200528030-00002","volume":"28","author":"JM Pierre","year":"2005","unstructured":"Pierre JM (2005) Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf 28(3):191\u2013208","journal-title":"Drug Saf"},{"key":"1207_CR45","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11883-002-0049-8","volume":"4","author":"P Poirier","year":"2002","unstructured":"Poirier P, Eckel RH (2002) Obesity and cardiovascular disease. Curr Atheroscler Rep 4:448\u2013453","journal-title":"Curr Atheroscler Rep"},{"key":"1207_CR46","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","volume":"60","author":"SG Potkin","year":"2003","unstructured":"Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR (2003) Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60:681\u2013690","journal-title":"Arch Gen Psychiatry"},{"key":"1207_CR47","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/15622970410029915","volume":"5","author":"P Schwenkreis","year":"2004","unstructured":"Schwenkreis P, Assion H-J (2004) Atypical antipsychotics and diabetes mellitus. World J Biol Psychiatry 5:73\u201382","journal-title":"World J Biol Psychiatry"},{"issue":"suppl 8","key":"1207_CR48","first-page":"S235","volume":"11","author":"GM Simpson","year":"2005","unstructured":"Simpson GM (2005) Atypical antipsychotics and the burden of disease. Am J Managed Care 11(suppl 8):S235\u2013S241","journal-title":"Am J Managed Care"},{"key":"1207_CR49","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.schres.2005.07.025","volume":"79","author":"R Tandon","year":"2005","unstructured":"Tandon R, Fleischhacker WW (2005) Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res 79:145\u2013155","journal-title":"Schizophr Res"},{"key":"1207_CR50","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.schres.2007.11.033","volume":"100","author":"R Tandon","year":"2008","unstructured":"Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ Jr, Okasha A, Singh B, Stein DJ, Olie JP, Fleischhacker WW, Moeller HJ, for the Section of Pharmacopsychiatry, World Psychiatric Association (2008) World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schiz Res 100:20\u201338","journal-title":"Schiz Res"},{"issue":"suppl 3","key":"1207_CR51","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0924-977X(00)80318-1","volume":"10","author":"BJ Vliet Van","year":"2000","unstructured":"Van Vliet BJ, Mos J, Van der Heijden JAM, Feenstra R, Kruse CG, Long SK (2000) DU 127090: a highly potent atypical dopamine receptor ligand\u2014a putative potent full spectrum antipsychotic with low EPS potential. Eur Neuropsychopharmacol 10(suppl 3):293","journal-title":"Eur Neuropsychopharmacol"},{"issue":"suppl 4","key":"1207_CR52","first-page":"34","volume":"68","author":"PJ Weiden","year":"2007","unstructured":"Weiden PJ (2007) Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. J Clin Psychiatry 68(suppl 4):34\u201339","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"1207_CR53","first-page":"72","volume":"4","author":"W Wolf","year":"2003","unstructured":"Wolf W (2003) DU-127090 Solvay\/H Lundbeck. Curr Opin Investig Drugs 4(1):72\u201376","journal-title":"Curr Opin Investig Drugs"},{"issue":"1 suppl 1","key":"1207_CR54","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0920-9964(03)80210-4","volume":"60","author":"H Yang","year":"2003","unstructured":"Yang H, Casey DE, Feenstra RW, Kruse CG, Long SK (2003) DU127090: a novel partial dopamine agonist with antipsychotic activity behavioral effects of DU127090 in Cebus non-human primates. Schizophrenia Res 60(1 suppl 1):370","journal-title":"Schizophrenia Res"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-008-1207-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-008-1207-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-008-1207-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T20:06:41Z","timestamp":1558642001000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-008-1207-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,4]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["1207"],"URL":"https:\/\/doi.org\/10.1007\/s00213-008-1207-7","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,4]]}}}